A Study of Skipping Radiation Therapy in People With Breast Cancer
NCT07895511
This study is recruiting at 7 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to find out whether it is safe to skip (omit) radiation therapy to the breast after lumpectomy in people with low-risk HER2-positive breast cancer who are receiving HER2-targeted therapy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- HER2-positive Breast Cancer
- Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Last updated on ClinicalTrials.gov
- October 26, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New Jersey · 3
- Memorial Sloan Kettering at Basking Ridge (All protocol activities) · Basking Ridge, NJ
- Memorial Sloan Kettering Monmouth (All Protocol Activities) · Middletown, NJ
- Memorial Sloan Kettering Bergen (All Protocol Activities) · Montvale, NJ
New York · 4
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities ) · Commack, NY
- Memorial Sloan Kettering Westchester (All Protocol Activities) · Harrison, NY
- Memorial Sloan Kettering Cancer Center (All protocol activites) · New York, NY
- Memorial Sloan Kettering Nassau (All protocol activities) · Rockville Centre, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.